Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kabos

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|July 3, 2025
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapyRachel M Layman, Hyo S Han, Hope S Rugo, et al.
The Lancet. Oncology|March 28, 2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b studyRachel M Layman, Hyo S Han, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to EstrogenHeather M Brechbuhl, Jessica Finlay-Schultz, Tomomi M Yamamoto, et al.
Molecular Cancer Therapeutics|March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerJohn J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2021
IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain MetastasesR Alejandro Márquez-Ortiz, Maria J Contreras-Zárate, Vesna Tesic, et al.
JCI Insight|February 12, 2020
Fibroblast subtypes define a metastatic matrisome in breast cancerHeather M Brechbuhl, Alexander S Barrett, Etana Kopin, et al.
Biorxiv : the Preprint Server for Biology|May 13, 2026
Estradiol Reprograms Microglia to Create an Immune-Suppressed Niche Permissive to Breast Cancer Brain MetastasisKaren L F Alvarez-Eraso, María J Contreras-Zárate, Andrew Goodspeed, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of ER+ breast cancer brain metastases in young and aged hostsMorgan S Fox, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|July 3, 2025
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapyRachel M Layman, Hyo S Han, Hope S Rugo, et al.
The Lancet. Oncology|March 28, 2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b studyRachel M Layman, Hyo S Han, Hope S Rugo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to EstrogenHeather M Brechbuhl, Jessica Finlay-Schultz, Tomomi M Yamamoto, et al.
Molecular Cancer Therapeutics|March 12, 2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerJohn J Tentler, Anastasia A Ionkina, Aik Choon Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2021
IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain MetastasesR Alejandro Márquez-Ortiz, Maria J Contreras-Zárate, Vesna Tesic, et al.
JCI Insight|February 12, 2020
Fibroblast subtypes define a metastatic matrisome in breast cancerHeather M Brechbuhl, Alexander S Barrett, Etana Kopin, et al.
Biorxiv : the Preprint Server for Biology|May 13, 2026
Estradiol Reprograms Microglia to Create an Immune-Suppressed Niche Permissive to Breast Cancer Brain MetastasisKaren L F Alvarez-Eraso, María J Contreras-Zárate, Andrew Goodspeed, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of ER+ breast cancer brain metastases in young and aged hostsMorgan S Fox, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast CancerSara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Pageof 10